<?xml version="1.0" encoding="UTF-8"?>
<p>
 <italic>a) Antiviral actions</italic>. During the 2003 SARS epidemic medicinal NO gas, a mixture of 0.8% NO and 99.2% N
 <sub>2</sub> was administered by Keyaerts 
 <italic>et al</italic> (
 <xref rid="b123-ijmm-46-02-0489" ref-type="bibr">123</xref>) and followed by prompt improvement in oxygenation and sustained patient benefit; following-up on this observation it was shown that NO donor compounds inhibited SARS-CoV replication 
 <italic>in vitro</italic>, a finding replicated by another team who also observed that besides S-nitroso-N-acetylpenicillamine (SNAP), IFN also inhibited SARS-CoV replication 
 <italic>in vitro</italic> (
 <xref rid="b124-ijmm-46-02-0489" ref-type="bibr">124</xref>), confirming results obtained by another team who showed that IFN stimulates iNOS and NO production for prompt antiviral action (
 <xref rid="b125-ijmm-46-02-0489" ref-type="bibr">125</xref>).
</p>
